ImmunityBio IBRX
NASDAQ IBRX
$10.28 +1.00 (+10.78%)
At close: Oct 2, 2026 · 4:00 PM EDT

ImmunityBio (IBRX) Gains from Sales and Divestitures (2016 - 2019)

Updated

ImmunityBio's Gains from Sales and Divestitures came in at -$4,000 for FY2020.

Analysis

ImmunityBio (IBRX) Gains from Sales and Divestitures (2016 - 2019) Analysis & Trends

Going back to FY2016, ImmunityBio's Gains from Sales and Divestitures data covers 4 years.

  • Per Business Quant, earlier years put Gains from Sales and Divestitures at -$209,000 in FY2018, -$64,000 in FY2017 and -$18,000 in FY2016.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 ImmunityBio 10.83 Bn 9.59 Bn 50.94 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2019 869,000.00
Jun 30, 2019 -869,000.00
Dec 31, 2018 -75,000.00
Sep 30, 2018 -44,000.00
Jun 30, 2018 -54,000.00
Mar 31, 2018 -36,000.00
Sep 30, 2017 -64,000.00
Jun 30, 2016 -3,000.00
Mar 31, 2016 -15,000.00
API Access

ImmunityBio Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=IBRX&period=max&api_key=YOUR_API_KEY